Skip to content

Research on intervention strategies for weight rebound after discontinuation of GLP-1 receptor agonists and the related mechanisms of gut microbiota

Research on intervention strategies for weight rebound after discontinuation of GLP-1 receptor agonists and the related mechanisms of gut microbiota

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126537
Enrollment
Unknown
Registered
2026-06-10
Start date
2026-06-10
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Group A (Control group):Simple drug discontinuation
Group D (Combined intervention group):Combination intervention group
Group B (High-protein diet alone):Simple high-protein diet
Group C (Low-dose maintenance alone):Low-dose medication maintenance group

Sponsors

Henan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. BMI >= 28; 2. Male waist circumference >= 90 cm, female waist circumference >= 85 cm; 3. Age: 18 to 70 years.

Exclusion criteria

Exclusion criteria: 1. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; exclude those with a history of pancreatitis. 2. Subjects with severe hepatic impairment or severe renal impairment (eGFR 5 times per week, averaging > 100 mL of liquor, > 250 mL of rice wine, or > 5 bottles of beer per occasion). 6. Those who have used antibiotics for 3 consecutive days or longer within the past 3 months. 7. Individuals with physical disabilities, severe mental disorders, or other conditions leading to inability to care for themselves, or inability to recall clearly and answer questions. 8. Those who have undergone gastrointestinal surgery (including bariatric surgery). 9. Those who cannot guarantee sufficient time to participate in this study.

Design outcomes

Primary

MeasureTime frame
Changes in weight before and after treatment;

Secondary

MeasureTime frame
Changes in whole-body body composition, dynamic blood glucose monitoring, glycated hemoglobin (HbA1c), lipid levels, kidney function, liver function, uric acid, and blood pressure;Changes in the composition and function of gut microbiota;

Countries

China

Contacts

Public ContactHuijuan Yuan

Henan Provincial People's Hospital

lmls3712@163.com+86 135 1389 1997

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026